The invention relates to a composition excellent in stability during storage and stability during utilization, and relates to a method of producing the composition. The composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), and includes 0.00002 to 0.2 parts by mass of the compound (B) with respect to 100 parts by mass of the compound (A),

(R.sub.1—COO).sub.n—R.sub.2—(NCO).sub.m  (1)

(R.sub.1—COO).sub.n—R.sub.2—(R.sub.3—R.sub.1).sub.m  (2)

wherein in general formulae (1) and (2), R.sub.1 is an ethylenically unsaturated group having 2 to 7 carbon atoms; R.sub.2 is a (m+n)-valent hydrocarbon group having 1 to 7 carbon atoms and optionally contains an ether group; R.sub.1 and R.sub.2 in the general formula (1) are the same as R.sub.1 and R.sub.2 in the general formula (2); in general formula (2), R.sub.3 is —NHC(═O)—; and n and m each represent an integer of one or two.

The invention relates to a composition excellent in stability during storage and stability during utilization, and relates to a method of producing the composition. The composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), and includes 0.00002 to 0.2 parts by mass of the compound (B) with respect to 100 parts by mass of the compound (A),

(R.sub.1—COO).sub.n—R.sub.2—(NCO).sub.m  (1)

(R.sub.1—COO).sub.n—R.sub.2—(R.sub.3—R.sub.1).sub.m  (2)

wherein in general formulae (1) and (2), R.sub.1 is an ethylenically unsaturated group having 2 to 7 carbon atoms; R.sub.2 is a (m+n)-valent hydrocarbon group having 1 to 7 carbon atoms and optionally contains an ether group; R.sub.1 and R.sub.2 in the general formula (1) are the same as R.sub.1 and R.sub.2 in the general formula (2); in general formula (2), R.sub.3 is —NHC(═O)—; and n and m each represent an integer of one or two.

The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases. ##STR00001##

The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases. ##STR00001##

The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases. ##STR00001##

The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases. ##STR00001##

The present invention is directed to a compound of formula I,

##STR00001##

wherein R.sub.1 comprises hydrogen, an alkyl group, or an aryl group; R.sub.2 comprises hydrogen or a methyl group; R.sub.3 comprises a divalent organic group; R.sub.4 comprises a divalent organic group; and X comprises oxygen, NH, or N(R.sub.5), wherein R.sub.5 comprises a monovalent organic group. The present invention is also directed towards polymers comprising a pendant carbamate-functional moiety comprising the structure:

##STR00002##

wherein R.sub.1 comprises hydrogen, an alkyl group, or an aryl group; R.sub.2 comprises hydrogen or a methyl group; R.sub.3 comprises a divalent organic group; R.sub.4 comprises a divalent organic group; and X comprises oxygen, NH, or N(R.sub.5) wherein R.sub.5 comprises a monovalent organic group. The present invention is also directed to methods of preparing such compounds and polymers, compositions comprising such polymers, and coatings produced from such compositions.

The present invention is directed to a compound of formula I,

##STR00001##

wherein R.sub.1 comprises hydrogen, an alkyl group, or an aryl group; R.sub.2 comprises hydrogen or a methyl group; R.sub.3 comprises a divalent organic group; R.sub.4 comprises a divalent organic group; and X comprises oxygen, NH, or N(R.sub.5), wherein R.sub.5 comprises a monovalent organic group. The present invention is also directed towards polymers comprising a pendant carbamate-functional moiety comprising the structure:

##STR00002##

wherein R.sub.1 comprises hydrogen, an alkyl group, or an aryl group; R.sub.2 comprises hydrogen or a methyl group; R.sub.3 comprises a divalent organic group; R.sub.4 comprises a divalent organic group; and X comprises oxygen, NH, or N(R.sub.5) wherein R.sub.5 comprises a monovalent organic group. The present invention is also directed to methods of preparing such compounds and polymers, compositions comprising such polymers, and coatings produced from such compositions.

Provided are compounds of formula (I), or a stereoisomer, mixture of stereoisomers, deuterated analog, tautomer, solvate or pharmaceutically acceptable salt thereof, compositions, method of making and uses thereof.

##STR00001##